Reviewed by Michael Gill, B. Sc.
25 Dasatinib Clinical Trials Near Me
Top Cities for Dasatinib Clinical Trials
Most Recent Dasatinib Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
10/2/2022
Phase 1
10/1/2022
Phase 2
8/25/2022
Phase 1 & 2

People take dasatinib, under the brand name SPRYCEL, to act as a cancer blocker for Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). Both adults and children take it.

What Are Dasatinib Clinical Trials?

There was a Phase 3 trial that started in June 2007 and the first results were posted in March 20017. The final results were posted in February 2017. It was sponsored by Bristol-Myers Squibb and there were 547 participants. They were randomly allocated, assigned in a parallel manner and there was no masking - it was open label.The patients were either given Dasatinib or the usual treatment - Imatinib. Both of these were in pill form.

These participants were given pretreatment every three months for up to a year. They were all newly diagnosed with Ph+ CML. They were looking for patients to have Major Molecular Response, Complete Cytogenic Response, and they also looked at the bone marrow of these participants.

Why Is Dasatinib Being Studied In Clinical Trials?

Researchers were looking for things to help people who were diagnosed with PH + CML and were looking for treatment. They wanted something that could be better than Imantinib.

How Does Dasatinib Treatment Work?

People can take dasatinib once a day at the same time - it does not matter if it is day or night. They can also take it with or without food. It is important that the pill is swallowed whole and is not crushed or chewed. It should be taken on a continual basis - the only time that it should be stopped is if the symptoms get worse over the course of that time.

There are some possible expected side effects.Taking it can make people feel more fatigued than usual. They may have headaches or muscle or joint aches, skin rashes, and they may also feel weaker. If they start feeling depressed after taking it, then they should talk to their doctor about this side effect.

When it comes to food or drinks, they should avoid grapefruit, grapefruit juice, St. John's wort, and medications like verapamil, ketoconazole, rifampin, phenytoin, and modafanil. Patients might need to monitor their sugar as well, since they might find themselves feeling hypoglycemic while taking it due to an increased metabolic effect.

Should someone decide to stop taking this, especially before their Ph + CML has gone into remission, then they risk it going from chronic to a blast stage where their symptoms will get worse and reduce their life expectancy even more.

What Are Some of the Breakthrough Clinical Trials Involving Dasatinib?

The aforementioned clinical trial is what helped Dasatinib get it to market and help people who have Ph + CML have a better quality.

Who Are The Key Opinion Leaders On Dasatinib Clinical Trial Research?

The National Library of Medicine published a study about Dasatinib. Ultimately, Dasatinib is something that can help the molecular response of people who have Ph + CML and can help improve their test results and improve the quality of their life.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13;121(24):4867-74. doi: 10.1182/blood-2013-03-490128. Epub 2013 Apr 25. https://pubmed.ncbi.nlm.nih.gov/236205742 Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23. https://pubmed.ncbi.nlm.nih.gov/288354403 Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26;3(6):851-861. doi: 10.1182/bloodadvances.2018025874. https://pubmed.ncbi.nlm.nih.gov/308859964 Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, Advani A, Nand S, Ravandi F, Mukherjee S, Sekeres MA. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood. 2018 Jun 21;131(25):2782-2788. doi: 10.1182/blood-2018-01-826693. Epub 2018 Apr 4. https://pubmed.ncbi.nlm.nih.gov/296184795 Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA, Khosla S, Koerber DM, Lagnado AB, Lawson DK, LeBrasseur NK, Lerman LO, McDonald KM, McKenzie TJ, Passos JF, Pignolo RJ, Pirtskhalava T, Saadiq IM, Schaefer KK, Textor SC, Victorelli SG, Volkman TL, Xue A, Wentworth MA, Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-456. doi: 10.1016/j.ebiom.2019.08.069. Epub 2019 Sep 18. Erratum in: EBioMedicine. 2020 Feb;52:102595. https://pubmed.ncbi.nlm.nih.gov/315423916 Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28. https://pubmed.ncbi.nlm.nih.gov/324637417 Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23;116(12):2070-7. doi: 10.1182/blood-2009-12-261586. Epub 2010 May 13. https://pubmed.ncbi.nlm.nih.gov/204668538 Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan;140(1):161-6. doi: 10.1016/j.ygyno.2015.11.003. Epub 2015 Nov 14. Review. https://pubmed.ncbi.nlm.nih.gov/265864159 Gonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME. A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mech Ageing Dev. 2021 Dec;200:111589. doi: 10.1016/j.mad.2021.111589. Epub 2021 Oct 21. Review. https://pubmed.ncbi.nlm.nih.gov/3468772610 Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. Clin Pharmacokinet. 2022 Jun 28. doi: 10.1007/s40262-022-01148-9. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/35764773